

Mini Review

Fading Memories, Enduring Humanity: Understanding Alzheimer's Disease in a Changing World

Wilkinson H, Gustafson R, Tanida Y, Borcharding T

Department of Clinical Laboratory, St. Ivan Rilski University Hospital, Bulgaria.

\* **Corresponding Author:** Borcharding T, Department of Clinical Laboratory, St. Ivan Rilski University Hospital, Bulgaria.

**Citation:** Borcharding T, Fading Memories, Enduring Humanity: Understanding Alzheimer's Disease in a Changing World 1(2), 2025

**Copyright:** ©2025 Borcharding T, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Received date:** October 08, 2025; **Accepted date:** October 13, 2025; **Published date:** October 18, 2025

**Keywords:** amyloid plaque formation, synaptic dysfunction, oxidative stress, amyloid plaques, cholinesterase inhibitors

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behavior. As one of the leading causes of dementia worldwide, it poses significant challenges not only to those diagnosed but also to families, caregivers, and healthcare systems. This article explores the biological basis, symptoms, risk factors, and current approaches to diagnosis and treatment of Alzheimer's disease. It also highlights the emotional and social impact of the condition and underscores the importance of early detection, supportive care, and ongoing research in improving quality of life and finding potential cures

Introduction

Alzheimer's disease is a chronic and irreversible brain disorder that gradually destroys cognitive functions. First identified by German psychiatrist Alois Alzheimer in 1906, the disease has since become one of the most pressing public health concerns, particularly among aging populations. With increasing life expectancy worldwide, the prevalence of Alzheimer's continues to rise, making awareness and understanding more critical than ever.

Causes and Pathophysiology

The exact cause of Alzheimer's disease remains unknown, but it is associated with abnormal changes in the brain. These include the accumulation of amyloid-beta plaques outside neurons and tau protein tangles inside neurons. These changes disrupt communication between brain cells, eventually leading to cell death and brain shrinkage. Genetic, environmental, and lifestyle

factors are believed to contribute to the development of the disease.

Pathophysiology of Alzheimer's Disease

The pathophysiology of Alzheimer's disease is complex and involves multiple interconnected processes

1. Amyloid Plaque Formation

One of the earliest events in Alzheimer's disease is the accumulation of amyloid-beta (A $\beta$ ) peptides. These peptides are derived from the cleavage of amyloid precursor protein (APP). Abnormal processing leads to the formation of insoluble A $\beta$  fragments that aggregate and form extracellular plaques. These plaques disrupt cell-to-cell communication and trigger inflammatory responses in the brain.

2 Neurofibrillary Tangles (Tau Pathology)

Inside neurons, the protein tau becomes abnormally phosphorylated. Normally, tau stabilizes microtubules, which are essential for nutrient transport within cells. In Alzheimer's disease, hyperphosphorylated tau forms twisted structures called neurofibrillary tangles. These tangles impair intracellular transport and lead to neuronal death.

## 2. **Synaptic Dysfunction and Neuronal Loss**

The combined effect of amyloid plaques and tau tangles results in synaptic dysfunction, meaning neurons lose their ability to communicate effectively. Over time, widespread neuronal loss occurs, particularly in areas like the hippocampus and cerebral cortex, which are crucial for memory and learning.

## 3. **Neuroinflammation**

Microglial cells (immune cells in the brain) become activated in response to amyloid deposits. Chronic activation leads to the release of inflammatory cytokines, which further damage neurons and accelerate disease progression.

## 4. **Oxidative Stress and Mitochondrial Dysfunction**

Increased production of reactive oxygen species (ROS) leads to oxidative damage of proteins, lipids, and DNA. Mitochondrial dysfunction reduces energy production, making neurons more vulnerable to degeneration.

## 5. **Braintrophy**

As neurons die, the brain undergoes shrinkage (atrophy). This is particularly evident in the hippocampus, leading to severe memory impairment as the disease progresses

## Clinical Features

### Symptoms and Stages

Alzheimer's disease progresses through several stages, each marked by worsening symptoms. Early signs include mild memory loss, confusion, and difficulty in finding words. As the disease advances, individuals may struggle with daily tasks, experience mood changes, and lose recognition of familiar people and places. In the late stages, patients

become completely dependent on others for care and may lose the ability to communicate.

### Risk Factors

Age is the most significant risk factor, with most cases occurring in individuals over 65. Other factors include family history, genetic predisposition (such as the presence of the APOE-e4 gene), cardiovascular conditions, and lifestyle choices like poor diet, lack of exercise, and smoking. Education level and mental stimulation also play a role in influencing cognitive reserve.

### Diagnosis and Treatment

Diagnosing Alzheimer's disease involves a combination of medical history, cognitive tests, neurological

examinations, and imaging techniques such as MRI or CT scans. While there is no cure, treatments focus on managing symptoms. Medications such as cholinesterase inhibitors and memantine may help improve cognitive function temporarily. Non-pharmacological approaches, including cognitive therapy and lifestyle modifications, are also important.

### Impact on Society and Caregivers

The burden of Alzheimer's disease extends beyond patients to families and caregivers. Emotional stress, financial strain, and physical exhaustion are common among those providing care. Social support systems, counseling, and community resources play a crucial role in helping caregivers cope with these challenges.

### Future Directions and Research

Ongoing research aims to better understand the disease and develop effective treatments. Advances in biotechnology, early diagnostic tools, and clinical trials offer hope for slowing or preventing disease progression. Public health initiatives focusing on awareness, early screening, and healthy aging are equally important.


### Conclusion

Alzheimer's disease is a multifactorial disorder with a complex pathophysiological basis involving amyloid plaques, tau tangles, and neurodegeneration. Although current treatments only manage symptoms, ongoing research offers hope for disease-modifying therapies. Early diagnosis and comprehensive care remain essential in improving patient outcomes and quality of life.

### References

1. Bennett, D.A.; Schneider, J.A.; Arvanitakis, Z.; Kelly, J.F.; Aggarwal, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology* 2006, 66, 1837–1844.
2. Kunkle, B.W.; Schmidt, M.; Klein, H.-U.; Naj, A.C.; Hamilton-Nelson, K.L.; Larson, E.B.; Evans, D.A.; De Jager, P.L.; Crane, P.K.; Buxbaum, J.D.; et al. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurol.* 2021, 78, 102–113.
3. Dunn, G.; Gaudia, L.; Lowenherz, J.; Barnes, M. Effects of reversing digits forward and digits backward and strategy use on digit span performance. *J. Psychoeduc. Assess.* 1990, 8, 22–33.

4. Nasreddine, Z.S.; Phillips, N.A.; Bedirian, V.; Charbonneau, S.; Whitehead, V, et al The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. *J. Am. Geriatr. Soc.* 2005, 53, 695–699.
5. Uranga, R.M.; Nishii, A.; Maung, J.N.; Mori, H.; Desrosiers, B.; Jacobs, J.; Hoose, K.S.; Schill, R.L.; Bagchi, D.P.; Guak, H.; et al. Effects of Beta-Catenin Deficiency on Adipose Tissue Physiology. *Mol. Metab.* 2025, 100, 102226.



This work is licensed under Creative Commons Attribution 4.0 License  
DOI:10/JNDD/2025/010

**Your next submission with**

**Olites Publishers will reach you the below assets**

- We follow principles of publication led by the Committee on Publication Ethics (COPE).
- Double-blind peer review process which is just as well as constructive.
- Permanent archiving of your article on our website
- Quality Editorial service
- Manuscript accessibility in different formats (PDF, Full Text)
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

Learn more: [Journal of Neuroscience and Neurodevelopmental Disorders - Olites Publishers \(olitespublishing.org\)](https://olitespublishing.org)